RedHill Biopharma Ltd.
RDHLDrugs in Pipeline
8
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
RHB-104
Crohn's Disease
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Crohn Disease
RHB-105
Helicobacter Pylori Infection
RHB-102
Gastroenteritis
Opaganib
COVID-19
Upamostat
SARS-CoV-2
BEKINDA
Irritable Bowel Syndrome With Diarrhea
ABC294640
Cholangiocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RHB-104 | Phase 3 | Crohn's Disease | - | - |
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) | Phase 3 | Crohn Disease | - | - |
RHB-105 | Phase 3 | Helicobacter Pylori Infection | - | - |
RHB-102 | Phase 3 | Gastroenteritis | - | - |
Opaganib | Phase 3 | COVID-19 | - | - |
Upamostat | Phase 2 | SARS-CoV-2 | - | - |
BEKINDA | Phase 2 | Irritable Bowel Syndrome With Diarrhea | - | - |
ABC294640 | Phase 2 | Cholangiocarcinoma | - | - |
Frequently asked questions
What is in RedHill Biopharma Ltd.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in RedHill Biopharma Ltd.'s (RDHL) pipeline across Phase 3, Phase 2. Its lead program is RHB-104 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RedHill Biopharma Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for RedHill Biopharma Ltd. (RDHL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RDHL biotech catalysts?→
Add RDHL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RedHill Biopharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.